Takeda Starts Vedolizumab Phase III Trials For Crohn’s Disease, Ulcerative Colitis
This article was originally published in PharmAsia News
Takeda initiated Japenese Phase III trials with the monoclonal antibody vedolizumab used in the treatment of moderate to severe ulcerative colitis and Crohn’s disease.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.